Combined mechanical circulatory support (VA-ECMO and Impella) for influenza-related myocarditis complicated by refractory cardiogenic shock resulted in 100% mortality within 18 days.
Observational (n=7)
No
Does combined VA-ECMO and Impella improve survival in patients with influenza-related myocarditis complicated by refractory cardiogenic shock compared to AMI- or DCM-related rCS?
Combined mechanical circulatory support with VA-ECMO and Impella was unable to prevent 100% mortality in patients with refractory cardiogenic shock due to influenza-related myocarditis, highlighting the devastating nature of this condition.
BACKGROUND: There is scarce evidence for mechanical circulatory support (MCS) in patients with influenza-related myocarditis complicated by refractory cardiogenic shock (rCS). We sought to investigate the impact of MCS using combined veno-arterial extracorporeal membrane oxygenation (VA-ECMO) and micro-axial flow pumps (the ECMELLA concept) in influenza-related myocarditis complicated by rCS. METHODS: This is a prospective, observational analysis from the single centre HAnnover Cardiac Unloading REgistry (HACURE) from two recent epidemic influenza seasons. We analysed patients with verified influenza-associated myocarditis complicated by rCS who were admitted to our intensive care unit (ICU) on MCS. Subsequently, we performed a propensity score (PS) matched analysis to patients with acute myocardial infarction (AMI) complicated by rCS and non-ischaemic cardiomyopathy (DCM) related rCS. RESULTS: We describe a series of seven patients with rCS-complicated influenza-related myocarditis (mean age 56±10 years, 58% male, influenza A (n=2)/influenza B (n=5)). No patient had been vaccinated prior to the influenza season. MCS was provided using combined VA-ECMO and Impella micro-axial flow pump. In two patients with out-of-hospital cardiac arrest, VA-ECMO had been implanted for extracorporeal cardiopulmonary resuscitation. All patients died within 18 days of hospital admission. By PS-based comparison to patients with AMI- or DCM-related rCS and combined MCS, 30-day mortality was significantly higher in influenza-related rCS. CONCLUSION: Despite initial stabilisation with combined MCS in patients with rCS-complicated influenza-related myocarditis, the detrimental course of shock could not be stopped and all patients died. Influenza virus infection potentially critically affects other organs besides the heart, leading to irreversible end-organ damage that MCS cannot compensate for and, therefore, results in a devastating outcome.
Sieweke et al. (Tue,) conducted a observational in Influenza-related myocarditis complicated by refractory cardiogenic shock (n=7). Combined VA-ECMO and micro-axial flow pumps (ECMELLA) vs. AMI- or DCM-related refractory cardiogenic shock on combined MCS was evaluated on 30-day mortality. Combined mechanical circulatory support (VA-ECMO and Impella) for influenza-related myocarditis complicated by refractory cardiogenic shock resulted in 100% mortality within 18 days.